Regulatory Bayer plans filings for cardiac amyloidosis imaging agent PharmaphorumArmed with new phase 3 data, Bayer is preparing to file a PET imaging agent that could accelerate the diagnosis of cardiac amyloidosis.CardiovascularRead full story pharminent May 7, 2026 (Last updated: May 7, 2026) Pharmaphorum Armed with new phase 3 data, Bayer is preparing to file a PET imaging agent that could accelerate the diagnosis of cardiac amyloidosis. Cardiovascular Read full story Post navigation Previous: Roche buys AI-powered diagnostics player PathAINext: Angelini inks $4.1B Catalyst buy to enter US rare disease market Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
